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ABSTRACT: At the cellular level, many neurodegenerative diseases (NDs), often considered proteinopathies, are characterized by the
accumulation of misfolded and damaged proteins into large insoluble aggregates. Prominent species that accumulate early and play fundamental
roles in disease pathogenesis are amyloid β (Aβ) and tau in Alzheimer disease, α-synuclein (α-syn) in Parkinson disease, and polyQ-expanded
huntingtin (Htt) in Huntington disease. Although significant efforts have focused on how the cell deals with these protein aggregates, why is it
that these misfolded proteins are not degraded normally in the first place? A vast body of literature supports the notion that the cell’s protein
degradation system for individual proteins—the ubiquitin proteasome system (UPS)—does not function sufficiently in many NDs. The proteasome
itself has received significant focus for years due to its obvious failure to degrade misfolded proteins in ND, but no general mechanism has
been uncovered. We have recently found that specific pathologically relevant oligomers can potently and directly inhibit the proteasome. What
is most interesting is that the misfolded protein’s primary amino acid sequence was irrelevant to its ability to inhibit. Instead, the culprit is the
3-dimensional shape of the misfolded oligomers. It turns out that many misfolded proteins in ND can take on this proteasome-impairing shape
suggesting that there could be a common mechanism for UPS impairment in many NDs. The proteasome is already an important target for
treating cancer, could it also be targeted to broadly treat ND?
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Ubiquitin Proteasome System Impairment in
Neurodegenerative Diseases and Aging
The proteasome in neurodegenerative diseases
A vast number of human, animal model, and cell model studies
have indicated that the ubiquitin proteasome system (UPS) is
impaired in various neurodegenerative diseases (NDs)—
Alzheimer, Parkinson, Huntington, prion, and others. It is not
understood why the proteasome fails to rid the cell of such misfolded proteins before they oligomerize, eventually forming large
aggregates. One explanation is, as proteasome activity decreases
with age, the cell is more susceptible to protein accumulation and
aggregation later in life, which is when NDs primarily occur, and
a wide range of literature supports this hypothesis.1–5 In fact,
impairment of the proteasome by mutagenesis or pharmacologic
inhibition in mice, by itself, can cause pathologies and symptoms
associated with ND.6 In addition, several well-known genetic
causes of Alzheimer disease (AD), Parkinson disease (PD), and
Amyotrophic Lateral Sclerosis (ALS) are due to disruptions of
the UPS pathway. Currently, we do not understand the agerelated decline of UPS function but it does correlate with the late
onset of many NDs. Proteasome function has been shown to be
impaired in most NDs,7–12 and a recent genome-wide association study has identified the UPS as a risk pathway for AD.13,14
However, it has been difficult to elucidate the mechanism of
inhibition that has been observed and though not all studies find
UPS impairment the majority do.
In AD, the earliest pathologic hallmarks correlating with
cognitive impairment is synaptic loss in the neocortex
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and hippocampus, which play important roles in learning and
memory. Interestingly, there is weak correlation between insoluble protein deposit pathology and disease severity, suggesting
that other elements are responsible for neurotoxicity. The AD
pathogenesis is characterized by the general accumulation of
proteins, including misfolded metastable proteins such as amyloid β(Aβ) and tau. Even α-synuclein (α-syn), the primary misfolded protein found in PD, accumulates in subsets of AD.
Huntingtin (htt) protein itself causes Huntington disease, when
its poly-glutamine (polyQ) track gets expanded (ie, CAG repeat
expansion), which slows its rapid degradation by the proteasome and it accumulates into aggregates. These misfolded proteins are normally degraded by the UPS (in their monomeric
forms), which demonstrates that the UPS obviously does not
function sufficiently to prevent their cellular accumulation in
these diseases. It is now widely understood that small soluble
oligomers play a key role in AD pathogenesis, which is based on
their measurable toxicities and correlation with the severity of
the disease.15–18 The most recent evidence indicates that specific
small soluble Aβ oligomers are likely to be the initiating neurotoxic species in AD.19–21 In a similar fashion, small soluble oligomers of tau are also found to be the earliest and most toxic
misfolded forms of tau18,22–24 that contribute to disease severity.
Although these 2 proteins spend most of their time isolated
from each other, with Aβ outside the cell and tau inside (especially in axons), they can also be found together. In fact, Aβ is
found in the cytosol with tau.25 Recent evidence showing that
toxic oligomers can travel along neuronal pathways from cell to
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a common mechanism for UPS impairment could be shared by
all of these diseases?

Normal Proteasome Function

Figure 1. The 26S proteasome. Ubiquitinated proteins bound to the 19S
are unfolded by the ATPases, which are injected through the opened gate
and into the 20S for degradation. The 19S can bind to one or both ends of
the 20S.

cell, in a transmissible-like fashion, also points to a small soluble
oligomers as pathogenic agents.26–28 Consistent with this model,
evidence also suggests that the incorporation of toxic oligomers
into large aggregates is actually protective for the cell,29–31 as
some large aggregates are inert. Of course, when aggregates
become large enough they can have other toxicities due to their
sheer size (eg, by disrupting membranes or sequestering proteostasis mechanisms such as protein chaperones or ubiquitin).32
Likewise, this narrative is also shared by oligomers of α-syn33,34
and htt,35,36 as evidence indicates that they too are likely the
most neurotoxic species; however, this hypothesis has not been
fully vetted especially regarding its generality. For instance,
poly(GA)-containing aggregates can sequester and impair proteasomes,37 whereas polyQ-containing aggregates do not.38
Taken together, recent evidence supports a model whereby soluble oligomers, perhaps even in cooperation with one another, are
the primary pathogenic drivers of ND.
At the risk of oversimplifying, AD is, to the best of our current knowledge, caused by the generation and accumulation of
particular misfolded proteins that can form pathologic (or
toxic) oligomers that impair synaptic function with associated
mitochondrial dysfunction and ultimately neuronal cell death.
Remarkably, the proteasome plays an essential role in maintaining all 3 of these critical cellular processes that go awry in
AD—misfolded protein degradation, synaptic function (LTP/
LTD),39,40 and mitochondrial function.41–43 Proteasome
impairment has been pointed to as a major contributor to AD
pathogenesis for years,23,44–48 as it has for many other NDs as
well,7–12,49 but the evidence has only been correlative and no
molecular mechanisms have been elucidated. Is it possible that

The principle degradative machinery of the UPS is the 26S
proteasome which is a 2.5 MDa molecular machine that
destroys the vast majority of proteins in the cell and its function
is critical as it regulates essentially every cellular process.50 It is
composed of an adenosine triphosphatase (ATPase) regulatory
complex (19S) that binds to one or both ends of the 20S core
proteasome51 where proteolysis occurs (Figure 1). The 20S is a
cylindrical complex with a hollow center. The 19S and its
ATPases (orange) are required for ubiquitin-dependent degradation of folded substrates. As tightly folded proteins are too
large to enter the 20S, the ATPases must use ATP to unfold
proteins and inject them into the 20S for degradation. The
outer rings of the 20S contain 7 α-subunits (α1-7; light blue)
with a central pore. Proteins must translocate through this pore
to enter the degradation chamber of 20S (β-subunits; dark
blue). The translocation of proteins through this channel constitutes a critical regulatory step in protein degradation as their
passage is restricted by the N-termini of the α-subunits, which
function as a substrate gate (Figure 1). The ATPase ring complex opens this gate, allowing substrate entry during protein
degradation, thus regulating proteolysis.52–55 The C-termini of
these ATPases have a 3-residue motif called the HbYX motif
that inserts into pockets on the outer α-ring of 20S that allows
the 19S to bind to the 20S and induce gate-opening.

A Common Mechanism of Proteasome Impairment

Considering that protein degradation by the proteasome
requires a complex multistep process, we reasoned that perhaps
pathologic oligomers impair one of the steps in protein degradation. Based on this, we investigated the hypothesis that there
exists a universal mechanism of proteasomal impairment in
NDs. We found that specific small soluble oligomers of 3 disease-related proteins (amyloid β, α-synuclein, and polyQexpanded Huntingtin) potently inhibit proteasome function,56
which as we have discussed is not a particularly novel concept.
The novel finding was that the amino acid sequence of the
protein is unimportant for its ability to inhibit the proteasome.
Instead, it is the misfolded tertiary structure of the protein that
is critical for proteasome inhibition. We found that small soluble oligomers of these 3 different proteins, when misfolded in a
similar conformation, bind to and inhibit the proteasome with
high affinity. These inhibitory oligomers are recognized by the
A11 antibody, are known to be neurotoxic, and have been found
in the brains of patients with different NDs. Our results thus
introduce a general mechanism of proteasome impairment
across the spectrum of NDs. We further demonstrated that
these oligomers inhibit ubiquitin-dependent protein degradation by allosterically stabilizing the closed state of the 20S gate,
thus inhibiting substrate entry.56 In short, A11+ oligomers
regardless of their primary sequence can prevent the 19S from

Smith

3

Figure 2. Pathologic oligomers from neurodegenerative diseases (NDs) inhibit the proteasome stabilizing its closed gate conformation. Misfolded
proteins that oligomerize and are A11+ are potent allosteric inhibitors of the 20S and 26S proteasome, providing a general mechanism for proteasome
impairment in protein misfolding disorders. Gate-opening by the HbYX mechanism directly opposes the allosteric inhibition by oligomers.

inducing gate-opening in the 20S, which is required for substrate injection and degradation. Because these inhibitory oligomers have been found in many different NDs, we posit that
this mechanism of proteasome impairment constitutes a general and shared mechanism in these diseases. Moreover, as the
inhibitory species of these ND-related proteins turns out to be
a very specific oligomer with a specific conformation (only
A11+ oligomers can inhibit), it is no surprise that some studies
failed to find proteasome impairment because the A11+ oligomers only form under the proper conditions and may not be
present in all model systems. Studies investigating proteasome
impairment in NDs typically use heterogeneous oligomer
preparation without accounting for the different conformational states of the oligomers. Further efforts will be required to
determine the extent to which this impairment mechanism
elicits a physiological response in model organisms and in
humans, but this initial discovery provides a tangible and direct
mechanism of proteasome impairment that can be investigated
in ND with currently available approaches. These findings thus
bolster therapeutic efforts that are already ongoing, to find activators of proteasome function, and this study provides a mechanistic framework to do so as the general structure of the 26S
proteasome is known (Figure 2).

Restoring and Enhancing Proteasome function in
NDs

Because the mechanism of inhibition by oligomers is due to an
allosteric effect on the 20S proteasome, it is possible that small

molecules may reverse inhibition by oligomers. In fact, we have
found that small peptides corresponding to the HbYX motif are
able to reverse inhibition by these A11+ oligomers. However,
the mechanism by which HbYX peptides induce gate-opening
in the 26S core particle is not well-understood. Recent structural
studies of the 26S proteasome indicate that understanding how
the 19S ATPases induce gate-opening is not trivial, and future
studies are required to clarify the mechanism. Nevertheless, the
cryo-EM structure of the homologous archaeal 20S proteasome
with the bound HbYX peptides has been generated.55 In this
structure, HbYX binding to intersubunit pockets on top of the
α-ring induces a rotation in the α-subunits, repositioning the
base of the gating residues from a closed to an open gate conformation. Understanding exactly where the A11+ oligomers bind
to the 20S and elucidating the conformational changes that
induce allosteric inhibition will be key to future efforts aimed at
developing small molecules to reverse the inhibition. In the
meantime, mutations to the 20S gating residues are also capable
of inducing gate-opening and we showed that these mutations
prevent allosteric inhibition by A11+ oligomers. Interestingly, a
study by Choi et al showed that a similar gate-opening mutation
enhances ubiquitin-dependent protein degradation in a human
cell line. Future efforts are required to determine whether such
mutations can alleviate proteasomal impairment in models of
ND. A common mechanism of proteasome impairment in ND
fits into the framework of what we have learned about protein
degradation in ND in recent decades. If this mechanism is ubiquitous in ND and plays a substantial pathologic role, then
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therapeutics that counteract this mechanism would be very
exciting, as they could provide a method for treating a fundamental component of ND. Regardless of this specific impairment mechanism, finding ways to activate proteasome function
would be expected to be beneficial to treat a root issue of these
devastating proteinopathies.

22.

Author Contributions

25.

This article commentary is written and prepared by DMS.

ORCID iD

David M Smith
References
1.

2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.

13.
14.
15.
16.
17.
18.
19.
20.
21.

https://orcid.org/0000-0002-1502-676X

Chondrogianni N, Gonos ES. Proteasome function determines cellular homeostasis and the rate of aging. Adv Exp Med Biol. 2010;694:38–46.
Mattson MP, Magnus T. Ageing and neuronal vulnerability. Nat Rev Neurosci.
2006;7:278–294.
Tomaru U, Takahashi S, Ishizu A, et al. Decreased proteasomal activity causes
age-related phenotypes and promotes the development of metabolic abnormalities. Am J Pathol. 2012;180:963–972.
Vigouroux S, Briand M, Briand Y. Linkage between the proteasome pathway
and neurodegenerative diseases and aging. Molec Neurobiol. 2004;30:201–221.
Zabel C, Nguyen HP, Hin SC, Hartl D, Mao L, Klose J. Proteasome and oxidative phosphorylation changes may explain why aging is a risk factor for neurodegenerative disorders. J Proteomics. 2010;73:2230–2238.
Bedford L, Hay D, Devoy A, et al. Depletion of 26S proteasomes in mouse brain
neurons causes neurodegeneration and Lewy-like inclusions resembling human
pale bodies. J Neurosci. 2008;28:8189–8198.
Myeku N, Clelland CL, Emrani S, et al. Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating
cAMP-PKA signaling. Nat Med. 2016;22:46–53.
Bennett E, Shaler T, Woodman B, et al. Global changes to the ubiquitin system
in Huntington’s disease. Nature. 2007;448:704–708.
Ciechanover A, Brundin P. The ubiquitin proteasome system in neurodegenerative
diseases: sometimes the chicken, sometimes the egg. Neuron. 2003;40:427–446.
Keller JN, Hanni KB, Markesbery WR. Impaired proteasome function in
Alzheimer’s disease. Brain. 2000;75:436–439.
Lam YA, Pickart CM, Alban A, et al. Inhibition of the ubiquitin-proteasome
system in Alzheimer’s disease. Proc Natl Acad Sci U S A. 2000;97:9902–9906.
Li L, Chin L-S. Impairment of the ubiquitin-proteasome system: a common
pathogenic mechanism in neurodegenerative disorders. In: Di Napoli M, Wojcik
C, eds. The Ubiquitin Proteasome System in the Central Nervous System: From Physiology to Pathology. New York, NY: Nova Science Publishers; 2007:553–577.
International Genomics of Alzheimer’s Disease Consortium. Convergent
genetic and expression data implicate immunity in Alzheimer’s disease. Alzheimers Dement. 2015;11:658–671.
Gentier RJ, van Leeuwen FW. Misframed ubiquitin and impaired protein quality control: an early event in Alzheimer’s disease. Front Mol Neurosci. 2015;8:47.
Barghorn S, Nimmrich V, Striebinger A, et al. Globular amyloid beta-peptide
oligomer—a homogenous and stable neuropathological protein in Alzheimer’s
disease. J Neurochem. 2005;95:834–847.
Lue L, Kuo Y, Roher A, et al. Soluble amyloid beta peptide concentration as a
predictor of synaptic change in Alzheimer’s disease. Am J Pathol.
1999;155:853–862.
Stefani M. Structural features and cytotoxicity of amyloid oligomers: implications in Alzheimer’s disease and other diseases with amyloid deposits. Prog Neurobiol. 2012;99:226–245.
Ward S, Himmelstein D, Lancia J, Binder L. Tau oligomers and tau toxicity in
neurodegenerative disease. Biochem Soc Trans. 2012;40:667–671.
Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D. Soluble
oligomers of amyloid Beta protein facilitate hippocampal long-term depression
by disrupting neuronal glutamate uptake. Neuron. 2009;62:788–801.
Lacor P, Buniel M, Furlow P, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J Neurosci. 2007;27:796–807.
Shankar GM, Li S, Mehta TH, et al. Amyloid-β protein dimers isolated directly
from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med.
2008;14:837–842.

23.
24.

26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.

46.
47.
48.

49.

Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, et al. Identification of
oligomers at early stages of tau aggregation in Alzheimer’s disease. FASEB J.
2012;26:1946–1959.
Deger JM, Gerson JE, Kayed R. The interrelationship of proteasome impairment
and oligomeric intermediates in neurodegeneration. Aging Cell.
2015;14:715–724.
Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, et al. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes
without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci.
2014;34:4260–4272.
LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer’s disease. Nat Rev Neurosci. 2007;8:499–509.
Desplats P, Lee H-JJ, Bae E-JJ, et al. Inclusion formation and neuronal cell death
through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U
S A. 2009;106:13010–13015.
Clavaguera F, Bolmont T, Crowther R, et al. Transmission and spreading of
tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11:909–913.
Luk K, Kehm V, Zhang B, O’Brien P, Trojanowski J, Lee V. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med. 2012;209:975–986.
Tompkins M, Hill W. Contribution of somal Lewy bodies to neuronal death.
Brain Res. 1997;775:24–29.
Arrasate M, Mitra S, Schweitzer E, Segal M, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death.
Nature. 2004;431:805–810.
Brouillette J, Caillierez R, Zommer N, et al. Neurotoxicity and memory deficits
induced by soluble low-molecular-weight amyloid-β1-42 oligomers are revealed
in vivo by using a novel animal model. J Neurosci. 2012;32:7852–7861.
Hipp MS, Patel CN, Bersuker K, et al. Indirect inhibition of 26S proteasome
activity in a cellular model of Huntington’s disease. J Cell Biol. 2012;196:573–587.
Rockenstein E, Nuber S, Overk CR, et al. Accumulation of oligomer-prone αsynuclein exacerbates synaptic and neuronal degeneration in vivo. Brain.
2014;137:1496–1513.
Colla E, Jensen PH, Pletnikova O, Troncoso JC, Glabe C, Lee MK. Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in αsynucleinopathy in vivo. J Neurosci. 2012;32:3301–3305.
Takahashi T, Kikuchi S, Katada S, Nagai Y, Nishizawa M, Onodera O. Soluble
polyglutamine oligomers formed prior to inclusion body formation are cytotoxic.
Hum Mol Genet. 2008;17:345–356.
Jimenez-Sanchez M, Licitra F, Underwood BR, Rubinsztein DC. Huntington’s
disease: mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb
Perspect Med. 2017;7:a024240.
Guo Q , Lehmer C, Martinez-Sanchez A, et al. In situ structure of neuronal
C9orf72 poly-GA aggregates reveals proteasome recruitment. Cell. 2018;172:696.
e12–705.e12.
Bauerlein FJB, Saha I, Mishra A, et al. In situ architecture and cellular interactions of PolyQ inclusions. Cell. 2017;171:179.e10–187.e10.
Jarome TJ, Helmstetter FJ. The ubiquitin-proteasome system as a critical regulator of synaptic plasticity and long-term memory formation. Neurobiol Learn
Mem. 2013;105:107–116.
Merlo E, Romano A. Long-term memory consolidation depends on proteasome
activity in the crab Chasmagnathus. Neuroscience. 2007;147:46–52.
Bragoszewski P, Turek M, Chacinska A. Control of mitochondrial biogenesis
and function by the ubiquitin-proteasome system. Open Biol. 2017;7:170007.
Lehmann G, Udasin RG, Ciechanover A. On the linkage between the ubiquitinproteasome system and the mitochondria. Biochem Biophys Res Commun.
2016;473:80–86.
Livnat-Levanon N, Glickman MH. Ubiquitin-proteasome system and mitochondria—reciprocity. Biochim Biophys Acta. 2011;1809:80–87.
Sulistio YA, Heese K. The ubiquitin-proteasome system and molecular chaperone deregulation in Alzheimer’s disease. Mol Neurobiol. 2016;53:905–931.
Liu Y, Hettinger CL, Zhang D, Rezvani K, Wang X, Wang H. The proteasome function reporter GFPu accumulates in young brains of the APPswe/
PS1dE9 Alzheimer’s disease mouse model. Cell Mol Neurobiol.
2014;34:315–322.
Bingol B, Sheng M. Deconstruction for reconstruction: the role of proteolysis in
neural plasticity and disease. Neuron. 2011;69:22–32.
Tseng BP, Green KN, Chan JL, Blurton-Jones M, Frank M. Abeta inhibits the
proteasome and enhances amyloid and tau accumulation. Neuroscience.
2009;29:1607–1618.
Zhang N-Y, Tang Z, Liu C-W. alpha-Synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation: understanding the cytotoxicity of protein
protofibrils in neurodegenerative disease pathogenesis. J Biol Chem.
2008;283:20288–20298.
Bennett EJ, Bence NF, Jayakumar R, Kopito RR. Global impairment of the
ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Molec Cell. 2005;17:351–365.

Smith
50.
51.
52.
53.

Finley D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu Rev Biochem. 2009;78:477–513.
Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine
designed for controlled proteolysis. Annu Rev Biochem. 1999;68:1015–1068.
Smith DM, Fraga H, Reis C, Kafri G, Goldberg AL. ATP binds to proteasomal
ATPases in pairs with distinct functional effects, implying an ordered reaction
cycle. Cell. 2011;144:526–538.
Smith DM, Chang SC, Park S, Finley D, Cheng Y, Goldberg AL. Docking of
the proteasomal ATPases’ carboxyl termini in the 20S proteasome’s alpha ring
opens the gate for substrate entry. Mol Cell. 2007;27:731–744.

5
54.
55.

56.

Rabl J, Smith DM, Yu Y, Chang SC, Goldberg AL, Cheng Y. Mechanism of
gate opening in the 20S proteasome by the proteasomal ATPases. Mol Cell.
2008;30:360–368.
Yu Y, Smith DM, Kim HM, Rodriguez V, Goldberg AL, Cheng Y. Interactions
of PAN’s C-termini with archaeal 20S proteasome and implications
for the eukaryotic proteasome-ATPase interactions. EMBO J. 2010;29:
692–702.
Thibaudeau TA, Anderson RT, Smith DM. A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers. Nat
Comm. 2018;9:1097.

